

INTERNATIONAL SEARCH REPORT

CITE NO. MK

International application No.
PCT/US00/00648

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : Please See Extra Sheet.
US CL : Please See Extra Sheet.
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
U.S. : 546/288, 289, 291, 300 ; 514/183, 222.2, 228.8, 588, 595, 597, 598; 564/49, 50, 52,

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAS ONLINE, REGISTRY, HCAPLUS
search terms : cancer, raf kinase

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 98/52558 A1 (BAYER CORPORATION) 26 November 1998, (26.11.98) especially Tables 1-4, pages 65-76.	1-67
Y	WO 98/52559 A1 (BAYER CORPORATION) 26 November 1998 (26.11.98), especially Tables 1-4, pages 15-17.	1-67
Y,P	Database HCAPLUS, DN 131:87909, DUMAS et al. 'Inhibition of P38 kinase activity using substituted heterocyclic ureas.' Abstract, WO 99/32111, 01 July 1999, see entire document.	1-67
Y,P	Database HCAPLUS, DN 131:73649, DUMAS et al. 'Preparation of pyrazolyl aryl ureas and related compounds as P38 kinase inhibitors.' Abstract, WO 99/32110, 01 July 1999, see entire document.	1-67

Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search
22 MAY 2000

Date of mailing of the international search report
29 JUN 2000

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231
Facsimile No. (703) 305-3230

Authorized officer
RITA DESAI
Telephone No. (703) 308-1235

Jerry Dey for

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US00/00648

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Database HCAPLUS, DN 127:293717, KURIK M.V. et al. 'Optical properties of segmented oligourethane with azomethine terminal fragments.' Abstract, Vysokomol. Soedin. 1996, Vol. 38, No. 12, pages 2038-2041, especially RN# 197149-54-5.	1-48,60 and 61
X	Database HCAPLUS, DN 127:34137, KUBO et al. 'Preparation of quinoline and quinazoline derivatives inhibiting platelet-derived growth factor receptor autophosphorylation.' Abstract, WO 97/17329. 15 May 1997, see entire document, especially RN # 190726-87-5, 190726-88-6, 190727-39-0, 190727-43-6.	1-67
X	Database HCAPLUS, DN 126:166148, WINKLER et al. 'Inhibitors of coenzyme A-independent transacylase induce apoptosis in human HL-60 cells.' Journal of Pharmacol. 1996, Vol. 279, No. 2, pages 956-966, see entire document, especially RN# 162793-63-7 and 187173-03-1.	1-67
X	Database HCAPLUS, DN 98:78152, CHUGAI PHARMACEUTICAL CO. LTD., JAPAN. 'Antitumor benzophenone derivatives.' Abstract, JP 57185219. 15 November 1982, see entire document, especially RN# 3086-71-4.	1-67
A	Database HCAPLUS, DN 72:79046, HIRT et al. 'Tuberculostatic and cancerstatic polybasic ureas.' Abstract, CH 479557. 15 October 1969, see entire document, especially RN# 5262-16-8.	1-67
X,P	Database HCAPLUS, DN 131:58658, MILLER et al. 'Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas.' Abstract, WO 99/32436. 01 July 1999, see entire document, especially RN# 228399-32-4.	1-67
X	Database HCAPLUS, DN 127:273945, DEARDEN et al. 'Quantitative structure-biodegradability studies: an investigation of the MITI aromatic compound database.' Nato ASI Srv. 1996, Vol. 23, pages 93-104, see entire document, especially RN# 24019-05-4.	1-48, 50 and 61
X	Database HCAPLUS, DN 125:245169, BONWICK et al. 'Production of murine monoclonal antibodies against sulcofuran and flucofuran by in-vitro immunization.' Journal of Immunological Methods. 1996, Vol. 196, No. 2, pages 163-173. See entire document, especially RN# 24019-05-04.	1-67